29,112 Shares in Novavax, Inc. (NASDAQ:NVAX) Purchased by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC acquired a new position in shares of Novavax, Inc. (NASDAQ:NVAX) during the third quarter, Holdings Channel.com reports. The fund acquired 29,112 shares of the biopharmaceutical company’s stock, valued at approximately $368,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Shah Capital Management lifted its holdings in Novavax by 19.0% during the 2nd quarter. Shah Capital Management now owns 9,662,090 shares of the biopharmaceutical company’s stock worth $122,322,000 after purchasing an additional 1,544,263 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Novavax by 940.7% during the 3rd quarter. SG Americas Securities LLC now owns 1,154,276 shares of the biopharmaceutical company’s stock worth $14,579,000 after purchasing an additional 1,043,363 shares in the last quarter. Farallon Capital Management LLC purchased a new stake in Novavax during the 1st quarter worth about $5,406,000. Renaissance Technologies LLC purchased a new stake in Novavax during the 2nd quarter worth about $14,055,000. Finally, Bank of New York Mellon Corp lifted its holdings in Novavax by 34.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 533,942 shares of the biopharmaceutical company’s stock worth $6,760,000 after purchasing an additional 136,472 shares in the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Trading Up 1.4 %

Shares of Novavax stock opened at $7.32 on Monday. The firm has a market capitalization of $1.17 billion, a PE ratio of -3.24 and a beta of 2.10. Novavax, Inc. has a 12 month low of $3.53 and a 12 month high of $23.86. The business’s 50-day moving average price is $11.26 and its 200-day moving average price is $12.45.

Novavax (NASDAQ:NVAX) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.07. The company had revenue of $84.51 million for the quarter, compared to analysts’ expectations of $65.80 million. The company’s revenue was down 54.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.26) earnings per share. As a group, analysts predict that Novavax, Inc. will post -1.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on NVAX. Jefferies Financial Group decreased their target price on Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, October 16th. JPMorgan Chase & Co. upped their target price on Novavax from $8.00 to $9.00 and gave the stock an “underweight” rating in a research note on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $19.00 target price on shares of Novavax in a research note on Tuesday, November 12th. Finally, B. Riley restated a “buy” rating and issued a $26.00 target price (up from $23.00) on shares of Novavax in a research note on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $17.83.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.